Insider Actions for Intra-Cellular Therapies Inc.
– Purchase
– Sale
1
– Number of Transactions
Date
Name
Transaction
Value
| 02/24/2023 |
Sharon Mates Chairman, President & CEO; Director |
30,000 | Derivative/Non-derivative trans. at $3.26 per share. | 97,800 |
| 02/24/2023 |
Sharon Mates Chairman, President & CEO; Director |
22,590 | Disposition at $47.03 per share. | 1,062,407 |
| 02/24/2023 |
Mark Neumann EVP, Chief Commercial Officer |
4,046 | Disposition at $47.12 per share. | 190,647 |
| 02/24/2023 |
Suresh Durgam SVP, Chief Medical Officer |
7,906 | Disposition at $47.14 per share. | 372,688 |
| 02/24/2023 |
Michael Halstead EVP and General Counsel |
7,906 | Disposition at $47.03 per share. | 371,819 |
| 02/24/2023 |
Lawrence J. Hineline SVP of Finance CFO |
7,455 | Disposition at $47.03 per share. | 350,608 |
| 02/23/2023 |
Sharon Mates Chairman, President & CEO; Director |
22,590 | Derivative/Non-derivative trans. at $0 per share. | 0 |
| 02/23/2023 |
Mark Neumann EVP, Chief Commercial Officer |
7,906 | Derivative/Non-derivative trans. at $0 per share. | 0 |
| 02/23/2023 |
Suresh Durgam SVP, Chief Medical Officer |
7,906 | Derivative/Non-derivative trans. at $0 per share. | 0 |
| 02/23/2023 |
Michael Halstead EVP and General Counsel |
7,906 | Derivative/Non-derivative trans. at $0 per share. | 0 |
| 02/23/2023 |
Lawrence J. Hineline SVP of Finance CFO |
7,455 | Derivative/Non-derivative trans. at $0 per share. | 0 |
| 02/21/2023 |
Sharon Mates Chairman, President & CEO; Director |
251 | Disposition at $49.6 per share. | 12,449 |
| 02/21/2023 |
Sharon Mates Chairman, President & CEO; Director |
2,502 | Disposition at $48.7 per share. | 121,847 |
| 02/21/2023 |
Sharon Mates Chairman, President & CEO; Director |
2,200 | Disposition at $47.35 per share. | 104,170 |
| 02/21/2023 |
Sharon Mates Chairman, President & CEO; Director |
22,895 | Disposition at $46.54 per share. | 1,065,533 |
| 02/21/2023 |
Mark Neumann EVP, Chief Commercial Officer |
635 | Disposition at $48.93 per share. | 31,070 |
| 02/21/2023 |
Mark Neumann EVP, Chief Commercial Officer |
123 | Disposition at $47.32 per share. | 5,820 |
| 02/21/2023 |
Mark Neumann EVP, Chief Commercial Officer |
3,140 | Disposition at $46.61 per share. | 146,355 |
| 02/21/2023 |
Suresh Durgam SVP, Chief Medical Officer |
75 | Disposition at $49.6 per share. | 3,720 |
| 02/21/2023 |
Suresh Durgam SVP, Chief Medical Officer |
806 | Disposition at $48.63 per share. | 39,195 |
| 02/21/2023 |
Suresh Durgam SVP, Chief Medical Officer |
800 | Disposition at $47.2 per share. | 37,760 |
| 02/21/2023 |
Suresh Durgam SVP, Chief Medical Officer |
6,673 | Disposition at $46.55 per share. | 310,628 |
| 02/21/2023 |
Michael Halstead EVP and General Counsel |
100 | Disposition at $49.6 per share. | 4,960 |
| 02/21/2023 |
Michael Halstead EVP and General Counsel |
1,100 | Disposition at $48.68 per share. | 53,548 |
| 02/21/2023 |
Michael Halstead EVP and General Counsel |
643 | Disposition at $47.23 per share. | 30,368 |
| 02/21/2023 |
Michael Halstead EVP and General Counsel |
9,296 | Disposition at $46.56 per share. | 432,821 |
| 02/21/2023 |
Lawrence J. Hineline SVP of Finance CFO |
94 | Disposition at $49.6 per share. | 4,662 |
| 02/21/2023 |
Lawrence J. Hineline SVP of Finance CFO |
900 | Disposition at $48.72 per share. | 43,848 |
| 02/21/2023 |
Lawrence J. Hineline SVP of Finance CFO |
800 | Disposition at $47.32 per share. | 37,856 |
| 02/21/2023 |
Lawrence J. Hineline SVP of Finance CFO |
8,649 | Disposition at $46.54 per share. | 402,524 |
| 02/18/2023 |
Sharon Mates Chairman, President & CEO; Director |
27,848 | Derivative/Non-derivative trans. at $0 per share. | 0 |
| 02/18/2023 |
Mark Neumann EVP, Chief Commercial Officer |
11,139 | Derivative/Non-derivative trans. at $0 per share. | 0 |
| 02/18/2023 |
Suresh Durgam SVP, Chief Medical Officer |
8,354 | Derivative/Non-derivative trans. at $0 per share. | 0 |
| 02/18/2023 |
Michael Halstead EVP and General Counsel |
11,139 | Derivative/Non-derivative trans. at $0 per share. | 0 |
| 02/18/2023 |
Lawrence J. Hineline SVP of Finance CFO |
10,443 | Derivative/Non-derivative trans. at $0 per share. | 0 |
| 02/17/2023 |
Lawrence J. Hineline SVP of Finance CFO |
1,689 | Disposition at $50.59 per share. | 85,446 |
| 02/17/2023 |
Lawrence J. Hineline SVP of Finance CFO |
52,279 | Disposition at $49.81 per share. | 2,604,016 |
| 02/17/2023 |
Lawrence J. Hineline SVP of Finance CFO |
53,968 | Derivative/Non-derivative trans. at $12.73 per share. | 687,012 |
| 12/30/2022 |
Rory Balfour Riggs Director |
321 | Award at $52.92 per share. | 16,987 |
| 12/30/2022 |
Robert L. van Nostrand Director |
97 | Award at $52.92 per share. | 5,133 |
| 12/19/2022 |
Joel S. Marcus Director |
5,000 | Disposition at $50.82 per share. | 254,100 |
| 12/13/2022 |
Sharon Mates Chairman, President & CEO; Director |
33,083 | Disposition at $55 per share. | 1,819,565 |
| 12/01/2022 |
Michael Halstead EVP and General Counsel |
22,796 | Disposition at $53.48 per share. | 1,219,130 |
| 12/01/2022 |
Michael Halstead EVP and General Counsel |
27,204 | Disposition at $53.94 per share. | 1,467,383 |
| 12/01/2022 |
Michael Halstead EVP and General Counsel |
50,000 | Derivative/Non-derivative trans. at $15.47 per share. | 773,500 |
| 11/07/2022 |
Joel S. Marcus Director |
5,000 | Disposition at $52.11 per share. | 260,550 |
| 11/07/2022 |
Joel S. Marcus Director |
5,000 | Disposition at $52.49 per share. | 262,450 |
